Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Morse Asset Management Inc

Morse Asset Management Inc trimmed its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 11.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,788 shares of the medical equipment provider's stock after selling 1,924 shares during the quarter. Intuitive Surgical comprises 1.8% of Morse Asset Management Inc's investment portfolio, making the stock its 16th biggest holding. Morse Asset Management Inc's holdings in Intuitive Surgical were worth $7,324,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Chilton Capital Management LLC raised its stake in shares of Intuitive Surgical by 614.3% during the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after buying an additional 43 shares in the last quarter. Parvin Asset Management LLC purchased a new position in shares of Intuitive Surgical during the 4th quarter worth approximately $26,000. Global Financial Private Client LLC raised its stake in shares of Intuitive Surgical by 253.3% during the 1st quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after buying an additional 38 shares in the last quarter. Elite Financial Inc. purchased a new position in shares of Intuitive Surgical during the 1st quarter worth approximately $26,000. Finally, Hurley Capital LLC purchased a new position in shares of Intuitive Surgical during the 4th quarter worth approximately $28,000. 83.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Intuitive Surgical news, SVP Mark Brosius sold 216 shares of the company's stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $563.11, for a total value of $121,631.76. Following the transaction, the senior vice president owned 907 shares in the company, valued at approximately $510,740.77. This represents a 19.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gary Loeb sold 1,700 shares of the stock in a transaction that occurred on Friday, April 25th. The stock was sold at an average price of $513.18, for a total transaction of $872,406.00. Following the completion of the sale, the executive vice president owned 2,245 shares of the company's stock, valued at approximately $1,152,089.10. The trade was a 43.09% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 4,998 shares of company stock worth $2,611,577 over the last quarter. 0.70% of the stock is currently owned by insiders.

Intuitive Surgical Price Performance

Shares of ISRG stock opened at $518.62 on Friday. Intuitive Surgical, Inc. has a 12-month low of $425.00 and a 12-month high of $616.00. The firm has a market capitalization of $185.88 billion, a price-to-earnings ratio of 76.04, a price-to-earnings-growth ratio of 5.50 and a beta of 1.64. The business has a 50 day simple moving average of $535.90 and a 200 day simple moving average of $536.21.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.71 by $0.10. The firm had revenue of $2.25 billion during the quarter, compared to the consensus estimate of $2.19 billion. Intuitive Surgical had a return on equity of 14.43% and a net margin of 28.41%. During the same period in the prior year, the firm posted $1.50 earnings per share. On average, equities analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ISRG. Deutsche Bank Aktiengesellschaft downgraded Intuitive Surgical from a "hold" rating to a "sell" rating and dropped their price target for the stock from $515.00 to $440.00 in a research report on Monday, June 9th. Evercore ISI lifted their price objective on Intuitive Surgical from $470.00 to $550.00 and gave the company an "in-line" rating in a research report on Tuesday, July 8th. Citigroup reiterated a "buy" rating and issued a $650.00 target price (up previously from $590.00) on shares of Intuitive Surgical in a report on Thursday, May 22nd. BTIG Research set a $566.00 price objective on Intuitive Surgical and gave the stock a "buy" rating in a research note on Monday, July 14th. Finally, Barclays reduced their price objective on Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, Intuitive Surgical currently has an average rating of "Moderate Buy" and an average price target of $592.86.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.